Resumen de acción SRRK Scholar Rock Holding Corporation, empresa biofarmacéutica, se centra en el descubrimiento, desarrollo y administración de medicamentos para el tratamiento de enfermedades graves en las que la señalización por factores de crecimiento proteínicos desempeña un papel fundamental. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Scholar Rock Holding Corporation Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Scholar Rock Holding Precios históricos de las acciones Precio actual de la acción US$45.56 Máximo en las últimas 52 semanas US$46.19 Mínimo de 52 semanas US$6.76 Beta 0.54 Cambio en 1 mes 22.94% Variación en 3 meses 421.88% Cambio de 1 año 124.21% Variación en 3 años 74.89% Variación en 5 años 273.44% Variación desde la OPV 193.94%
Noticias y actualizaciones recientes
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High Dec 24
Price target increased by 15% to US$42.88 Nov 25 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Price target increased by 11% to US$29.75 Oct 07 Ver más actualizaciones
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High Dec 24
Price target increased by 15% to US$42.88 Nov 25 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Price target increased by 11% to US$29.75 Oct 07
Scholar Rock: SMA Program Strides Forward With Positive Clinical Data Oct 07
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy Oct 07
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer Sep 04
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt? Aug 13
New major risk - Financial position Aug 09
Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal Jun 24
CFO, COO & Treasurer recently sold US$85k worth of stock Jun 20
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting May 29
Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024 May 01
New major risk - Shareholder dilution Apr 19
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt? Apr 15
Price target increased by 8.1% to US$26.25 Mar 28
New minor risk - Share price stability Mar 21
New major risk - Financial position Mar 19
President recently sold US$183k worth of stock Feb 22
Scholar Rock Announces Management Appointments Feb 15
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management Feb 06
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity Jan 23
Scholar Rock: Solid Data And Good Prospects Jan 12
CFO, COO & Treasurer notifies of intention to sell stock Jan 01
Senior VP & Head of Research recently sold US$295k worth of stock Dec 17
CFO, COO & Treasurer notifies of intention to sell stock Dec 10
Price target increased by 7.1% to US$25.71 Dec 08
New major risk - Revenue and earnings growth Nov 08
CFO, COO & Treasurer notifies of intention to sell stock Nov 05
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability Nov 04
Price target increased by 9.8% to US$24.00 Oct 26
Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting Oct 20 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million. Oct 13
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial Sep 20
Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab Jul 01
Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023 May 04
Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up Apr 19
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 09
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer Feb 07
Price target decreased to US$22.57 Nov 19
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021) Nov 16
Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy Nov 11
Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer Nov 10
Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA Oct 23
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy Oct 20 Scholar Rock Announces Chief Executive Officer Changes
Jay Backstrom is the new CEO at Scholar Rock Sep 20
Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021) Aug 10
Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors Jul 27
Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology Jul 12 Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index
Price target decreased to US$29.00 Jun 23
Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment Jun 18
Consensus revenue estimates increase by 75% May 25
Consensus revenue estimates increase by 75% May 23
Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts May 21
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 17 Scholar Rock Holding Corporation Provides Pipeline Updates
Price target decreased to US$44.67 Apr 27
Price target decreased to US$46.17 Mar 23
Consensus forecasts updated Mar 14
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 09
Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher Mar 08
Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022 Jan 12
Price target decreased to US$55.80 Dec 24
Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Dec 01
CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock Nov 17
Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020) Nov 11
Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress Sep 24
Consensus forecasts updated Aug 19
Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020) Aug 12
Board Member notifies of intention to sell stock Jul 31
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress Jun 19
Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 12
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 08
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy May 25
Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting May 21
Forecast to breakeven in 2025 May 19
First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020) May 16
Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be May 15
Consensus revenue estimates fall to US$22.8m May 15
Price target decreased to US$64.00 May 15 Rentabilidad de los accionistas SRRK US Biotechs Mercado US 7D 8.2% 2.1% 2.8% 1Y 124.2% -3.8% 24.5%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: SRRK superó a la industria US Biotechs, que obtuvo un rendimiento del -3.8% el año pasado.
Rentabilidad vs. Mercado: SRRK superó al mercado US, que obtuvo un rendimiento del 24.5% el año pasado.
Volatilidad de los precios Is SRRK's price volatile compared to industry and market? SRRK volatility SRRK Average Weekly Movement 103.4% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: El precio de las acciones de SRRK ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SRRK ha aumentado de 52% a 103% en el último año.
Acerca de la empresa Scholar Rock Holding Corporation, empresa biofarmacéutica, se centra en el descubrimiento, desarrollo y administración de medicamentos para el tratamiento de enfermedades graves en las que la señalización por factores de crecimiento proteicos desempeña un papel fundamental. La empresa desarrolla Apitegromab, un inhibidor de la activación de la miostatina que se encuentra en ensayo clínico de fase 3 para el tratamiento de la atrofia muscular espinal; y SRK-181, que ha completado ensayos clínicos de fase 1 para el tratamiento de cánceres resistentes a terapias con inhibidores de puntos de control, como las terapias con anticuerpos anti-PD-1 o anti-PD-L1. Está desarrollando una cartera de productos candidatos para administrar terapias novedosas para tratar una serie de enfermedades graves, como trastornos neuromusculares, trastornos cardiometabólicos, cáncer, fibrosis y anemia con restricción de hierro.
Mostrar más Resumen de fundamentos de Scholar Rock Holding Corporation ¿Cómo se comparan los beneficios e ingresos de Scholar Rock Holding con su capitalización de mercado? Estadísticas fundamentales de SRRK Capitalización bursátil US$4.27b Beneficios(TTM ) -US$225.97m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-18.9x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de SRRK Ingresos US$0 Coste de los ingresos US$169.15m Beneficio bruto -US$169.15m Otros gastos US$56.82m Beneficios -US$225.97m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -2.41 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 63.3%
¿Cómo se ha desempeñado SRRK a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/26 05:19 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Scholar Rock Holding Corporation está cubierta por 16 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Madhu Kumar Baird Etzer Darout BMO Capital Markets Equity Research Guyn Kim BMO Capital Markets Equity Research
Mostrar 13 más analistas 
